Policy brief: HTA on sildenafil as treatment for pulmonary arterial hypertension

07 September 2017

With support from ADP and other technical partners, Indonesia recently conducted HTA on sildenafil. This issue brief provides a summary of the evaluation that was implemented, which resulting in the finding that sildenafil is a more cost-effective treatment option for pulmonary arterial hypertension (PAH), compared to treatment currently used. Sildenafil was thus recommended to be included in the national health insurance benefit package.